Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

A randomized, placebo-controlled phase 2–3 trial examined the safety, immunogenicity, and efficacy of two doses of the BNT162b2 vaccine administered 21 days apart in 5-to-11-year-old children.

2,268 children were randomly assigned to receive two injections, 21 days apart, of either the BNT162b2 vaccine (at a dose level of 10 μg, selected during phase 1) or placebo. Outcomes included immunogenicity, adverse events, and efficacy against confirmed Covid-19.

‍

Read the original article, as published on November 9, 2021 in the  New England Journal of Medicine.

‍

read the article